AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14684757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin C (approximately 70 mg/day)
Number of subjects: 11
Study 10947757 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40
Study 10947757 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 9233735 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐1ra (100 mg) followed by a 72‐hr continuous intravenous infusion of rhIL‐1ra (2.0 mg/kg/hr)
Number of subjects: 696
Study 9233735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) followed by a 72‐hr continuous intravenous infusion of placebo
Number of subjects: 696
Study 9233735 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐1ra
Number of subjects: 696
Study 9233735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 8497364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 53
Study 8497364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8497364 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to metronidazole gel
Number of subjects: 53
Study 8497364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 53
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BFM protocol
Number of subjects: 382
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BFM protocol (SR group)
Number of subjects: 382
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BFM protocol (HR group)
Number of subjects: 382
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month maintenance therapy
Number of subjects: 382
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDMTX) plus intrathecal methotrexate
Number of subjects: 382
Study 3305215 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus intrathecal methotrexate
Number of subjects: 382
Study 29476019 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg fresolimumab
Number of subjects: 23
Study 29476019 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg fresolimumab
Number of subjects: 23
Study 29476019 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (three doses of 7.5 Gy)
Number of subjects: 23
Study 26622051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone (250 mg) every 2 weeks for 24 weeks
Number of subjects: 94
Study 26622051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL saline) every 2 weeks for 24 weeks
Number of subjects: 94
Study 24605710 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency and lateral displacement of the inferior turbinate
Number of subjects: 60
Study 24605710 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency alone
Number of subjects: 60
Study 21862223 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 47
Study 21862223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19949163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 18274461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 18274461 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 18274461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study 16222197 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 625 mg/day (n = 25)
Number of subjects: 53
Study 16222197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 53
Study 11906981 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Disclosure Protocol (GDP) group (n = 22)
Number of subjects: 41
Study 11906981 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 41
Study 10150266 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin 30 mg
Number of subjects: 100
Study 10150266 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin 60 mg
Number of subjects: 100
Study 10150266 — intervention group
Group type: COMPARATOR
Intervention: Oramorph SR 60 mg
Number of subjects: 100
Study 3122699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (dosage not specified)
Number of subjects: 12
Study 3122699 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma metabolite concentrations
Number of subjects: 12
Study 3122699 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HB levels
Number of subjects: 12
Study 31505892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern Management (PM) education using continuous glucose monitoring system (CGMS) results
Number of subjects: 0
Study 31505892 — intervention group
Group type: COMPARATOR
Intervention: Traditional diabetes education (Control)
Number of subjects: 0
Study 28590765 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 41
Study 28590765 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (rest, NSAİİ, bracing, exercise)
Number of subjects: 41
Study 26254125 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure during acute hypoxia
Number of subjects: 57
Study 26254125 — intervention group
Group type: COMPARATOR
Intervention: Common artificial light exposure during acute hypoxia
Number of subjects: 57
Study 23163825 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 200 mg/day
Number of subjects: 13
Study 23163825 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/day
Number of subjects: 13
Study 20817148 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Person-Based Cognitive Therapy (PBCT)
Number of subjects: 62
Study 19366676 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 200
Study 19366676 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 200
Study 19366676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16679299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10-20 mg once daily
Number of subjects: 26
Study 16679299 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50-100 mg once daily
Number of subjects: 26
Study 15572814 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G + Chloramphenicol (n:46)
Number of subjects: 97
Study 15572814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (n:51)
Number of subjects: 97
Study 11734580 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet
Number of subjects: 10
Study 11734580 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 10
Study 9204351 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 300 mg I/ml
Number of subjects: 518
Study 9204351 — intervention group
Group type: COMPARATOR
Intervention: iopromide 300 mg I/ml
Number of subjects: 518
Study 8215565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lipid containing parenteral nutrition
Number of subjects: 129
Study 8215565 — intervention group
Group type: COMPARATOR
Intervention: Late lipid containing parenteral nutrition
Number of subjects: 129
Study 3379988 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory home care (RHC)
Number of subjects: 301
Study 3379988 — intervention group
Group type: COMPARATOR
Intervention: Standard home care (SHC)
Number of subjects: 301
Study 3379988 — intervention group
Group type: COMPARATOR
Intervention: Office care (OC)
Number of subjects: 301
Study 3379988 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (RHC, SHC, OC)
Number of subjects: 301
Study 31763749 — intervention group
Group type: EXPERIMENTAL
Intervention: PINC parent-training program
Number of subjects: 57
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure monitoring
Number of subjects: 305
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure measurement at induction
Number of subjects: 305
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure aim for supraglottic airway devices
Number of subjects: 305
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure aim for endotracheal tubes
Number of subjects: 305
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to cuff pressure manometer
Number of subjects: 305
Study 31280594 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for cuff pressure manometer
Number of subjects: 305
Study 28985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1 mg/kg IV bolus 10 hours before surgery)
Number of subjects: 161
Study 28985195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 28985195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 161
Study 25765602 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐Induced Aphasia Therapy (CIAT)
Number of subjects: 9
Study 25765602 — intervention group
Group type: COMPARATOR
Intervention: Semantic therapy (BOX)
Number of subjects: 9
Study 23468874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 cfu)
Number of subjects: 29
Study 23468874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22064013 — intervention group
Group type: EXPERIMENTAL
Intervention: Six hour simulation-based programme in care of a patient with physiological deterioration
Number of subjects: 31
Study 22064013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 31
Study 19204212 — intervention group
Group type: EXPERIMENTAL
Intervention: GP training plus cost-free nicotine replacement medication and/or bupropion hydrochloride
Number of subjects: 577
Study 19204212 — intervention group
Group type: EXPERIMENTAL
Intervention: GP training plus GP remuneration for each abstinent patient
Number of subjects: 577
Study 19204212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GP training plus GP remuneration and cost-free nicotine replacement medication and/or bupropion hydrochloride
Number of subjects: 577
Study 19204212 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 577
Study 17322142 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg IV on day 4, followed by 100 mg IV on days 5-13)
Number of subjects: 20
Study 17322142 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (5 mg orally on days 1 and 13)
Number of subjects: 20
Study 15068946 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (80 kV, 135 mAs)
Number of subjects: 142
Study 15068946 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (80 kV, 180 mAs)
Number of subjects: 142
Study 15068946 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (120 kV, 90 mAs)
Number of subjects: 142
Study 11450875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated fire-fighting tasks (boundary cooling, drum carry, extinguisher carry, hose run, ladder climb)
Number of subjects: 49
Study 11450875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated fire-fighting tasks
Number of subjects: 49
Study 11450875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated fire-fighting tasks with SCBA
Number of subjects: 49
Study 11450875 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max recommendation
Number of subjects: 49
Study 9806253 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (nafarelin acetate/Synarel) at a dosage of 200 microg three times daily until HCG administration
Number of subjects: 64
Study 9806253 — intervention group
Group type: COMPARATOR
Intervention: GnRHa (nafarelin acetate/Synarel) reduced to 200 microg twice daily as ovarian stimulation was initiated
Number of subjects: 64
Study 9050471 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy with bilateral salpingo-oophorectomy (LAVH-BSO)
Number of subjects: 40
Study 9050471 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO)
Number of subjects: 40
Study 3347522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalocaudal stroking procedure
Number of subjects: 81
Study 3347522 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory hammock with auditory, vestibular, and tactile stimulation
Number of subjects: 81
Study 3347522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cephalocaudal stroking and multisensory hammock
Number of subjects: 81
Study 3347522 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural stimulation in home environments)
Number of subjects: 81
Study 29795368 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (PS) 2 g/d
Number of subjects: 161
Study 29795368 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fat spreads without added PS)
Number of subjects: 161
Study 29122147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cardiac rehabilitation (CR) with stress management training (SMT)
Number of subjects: 119
Study 29122147 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR) without stress management training (SMT)
Number of subjects: 119
Study 29122147 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity (PA)
Number of subjects: 119
Study 26790552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 120
Study 26790552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 120
Study 26790552 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 120
Study 23731717 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of pulpally involved teeth
Number of subjects: 145
Study 21187254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led nonpharmacologic intervention (4 home visits by a nurse)
Number of subjects: 349
Study 21187254 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 349
Study 21187254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 349
Study 21187254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 349
Study 18441530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HB‐Hib vaccine (Hebervac HB‐Hib)
Number of subjects: 25
Study 18441530 — intervention group
Group type: COMPARATOR
Intervention: HB vaccine (Heberbiovac‐HB) and Hib vaccine (QuimiHib)
Number of subjects: 25
Study 16569462 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance gemcitabine (1,250 mg/m² on days 1 and 8 every 21 days) plus best supportive care (GEM arm)
Number of subjects: 352
Study 16569462 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care only (BSC arm)
Number of subjects: 352
Study 16569462 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance gemcitabine (GEM arm)
Number of subjects: 352
Study 12714194 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical cardioversion
Number of subjects: 139
Study 12714194 — intervention group
Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 139
Study 12714194 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 139
Study 12714194 — intervention group
Group type: COMPARATOR
Intervention: Electrical procedure
Number of subjects: 139
Study 10934454 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 16
Study 10934454 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 16
Study 8737166 — intervention group
Group type: COMPARATOR
Intervention: 0 MJ preload
Number of subjects: 37
Study 8737166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.26 MJ preload
Number of subjects: 37
Study 8737166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.51 MJ preload
Number of subjects: 37
Study 8737166 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 g preload
Number of subjects: 37
Study 8737166 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 g preload
Number of subjects: 37
Study 8737166 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 g preload
Number of subjects: 37
Study 1559192 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (2.5, 5, 10 or 20 mg bid for four weeks)
Number of subjects: 25
Study 1559192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for four weeks prior to quinapril therapy)
Number of subjects: 25
Study 3926036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low residue liquidized diet (Isocal) administered to treatment group
Number of subjects: 50
Study 3926036 — intervention group
Group type: COMPARATOR
Intervention: Routine intravenous therapy administered to control group
Number of subjects: 50
Study 31672256 — intervention group
Group type: EXPERIMENTAL
Intervention: Visco-ease™ oral spray
Number of subjects: 43
Study 31672256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30598489 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based intervention (iSOMA) for 8 weeks
Number of subjects: 154
Study 30598489 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 154
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid algorithm for CTO-PCI
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade wire escalation
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive strategies
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade dissection re-entry
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde strategies
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure time
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy time
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast volume
Number of subjects: 1177
Study 27788851 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation doses
Number of subjects: 1177
Study 24063767 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA plus DHA supplementation (0, 1, 2 or 4 portions of oily fish per week for 12 months)
Number of subjects: 0
Study 22541039 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment not detailed)
Number of subjects: 105
Study 22541039 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders
Number of subjects: 105
Study 22541039 — intervention group
Group type: COMPARATOR
Intervention: Non-responders (control group)
Number of subjects: 105
Study 20196067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 42376
Study 20196067 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination adjusted prostate cancer screening
Number of subjects: 42376
Study 20196067 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance adjusted prostate cancer screening
Number of subjects: 42376
Study 20196067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully adjusted prostate cancer screening
Number of subjects: 42376
Study 17323135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation (500 microg daily)
Number of subjects: 9
Study 15334317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (Rb) 400 mg twice a day, tetracycline (T) 1 g twice a day, metronidazole (M) 500 mg three times a day for 14 days (RbTM)
Number of subjects: 52
Study 15334317 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate (Rb) 400 mg twice a day for 14 days and azithromycin (A) 500 mg once a day for 7 days (RbA)
Number of subjects: 52
Study 11261502 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg glatiramer acetate (GA)
Number of subjects: 239
Study 9820378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal feeding
Number of subjects: 6
Study 9820378 — intervention group
Group type: COMPARATOR
Intervention: Intragastric feeding
Number of subjects: 6
Study 8087328 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 40 mg
Number of subjects: 276
Study 8087328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 2666019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloprovera (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Number of subjects: 130
Study 2666019 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP-102 (norethisterone enanthate 50 mg + estradiol valerate 5 mg)
Number of subjects: 130
Study 140037 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil in combination with frusemide and propranolol
Number of subjects: 30
Study 140037 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine in combination with frusemide and propranolol
Number of subjects: 30
Study 31829481 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) training (2×/week)
Number of subjects: 80
Study 31829481 — intervention group
Group type: COMPARATOR
Intervention: Nutritional support (Control group)
Number of subjects: 80
Study 31511291 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed health choices (IHC) resources
Number of subjects: 85
Study 28409242 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine with 20 mg ketamine (RK group)
Number of subjects: 66
Study 28409242 — intervention group
Group type: COMPARATOR
Intervention: Topical ropivacaine with saline (RS group)
Number of subjects: 66
Study 25549910 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self-regulatory intervention
Number of subjects: 166
Study 25549910 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 166
Study 24398192 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Optical Entry (DOE)
Number of subjects: 224
Study 24398192 — intervention group
Group type: COMPARATOR
Intervention: Open Hasson Technique (OHT)
Number of subjects: 224
Study 20694567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration (V) with G-Cem (GC)
Number of subjects: 56